huprot human proteome microarray version 4.0 (CDI Laboratories)
Structured Review

Huprot Human Proteome Microarray Version 4.0, supplied by CDI Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/huprot+human+microarray/huprot+human+proteome+microarray/pmc11701132-283-0-9
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss"
Article Title: Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss
Journal: Cell Research
doi: 10.1038/s41422-024-01016-0
Figure Legend Snippet: a The schematic diagram of human proteome microarray, which contains over 20,000 individual proteins printed in duplicate, to identify binding partners of high-dose and low-dose dexamethasone, respectively. b , c Human proteome microarray analysis reveals the proteins (in blue) which bind to both low and high-dose dexamethasone, and proteins (in green) which selectively bind to high-dose dexamethasone. d Principle of DARTS assay for the isolation of proteins protected from degradation by dexamethasone. e Dexamethasone protects two groups of protein bands (highlighted in black rectangle) from degradation in DARTS using whole cell lysate from dexamethasone-treated Raw264.7 cells coupled with Coomassie blue staining. f Molecular weight (MW) plot of putative high-dose dexamethasone-binding proteins identified by human proteome microarray analysis. g The protective effects of serial doses of dexamethasone on Tau and GR from digestion by protease are evaluated by DARTS coupled with immunoblotting. GAPDH is resistant to protease under the condition and serves as a loading indicator. Representative image is shown ( n = 3). h Quantification of Tau and GR stability treated with serial dosages of dexamethasone assayed by DARTS ( n = 3). i The interaction between dexamethasone and Tau, assayed by solid phase binding. 10 mM Tau was coated to the plate, and a serial dilution of biotin-labeled dexamethasone was added, followed by incubation with HRP-labeled Streptavidin and its substrate ( n = 3). Inset shows the Scatchard plot analysis for K D value calculation. j – p One-step kinetic SPR assay for binding of Tau to different GCs, as indicated. q qRT-PCR analysis of Tau mRNA levels in different tissues, as indicated ( n = 3). r Double-immunoflurorescence staining of femur section using antibodies against Tau (green) and TRAP, osteocalcin (OCN) and sclerostin (SOST) (red). DAPI stains nuclei. Arrows indicate positive staining cells. Scale bar = 20 µm. BM, bone marrow. Data are means ± SD in h , i , q .
Techniques Used: Microarray, Binding Assay, Isolation, Staining, Molecular Weight, Western Blot, Serial Dilution, Labeling, Incubation, SPR Assay, Quantitative RT-PCR
Related Articles
Microarray:Article Title: Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis Article Snippet: Frozen supernatants from polyclonally stimulated B cells were delivered to Cambridge Protein Arrays Ltd. (Cambridge, United Kingdom). .. Samples were analyzed using HuProt v4.0 Article Title: Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis Article Snippet: Background and Objectives Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease of the CNS.. Highlighted by the success of B-cell–depleting therapies such as the monoclonal anti-CD20 antibodies rituximab, ocrelizumab, and ofatumumab, B cells have been shown to play a central role in the immunopathology of the disease.. Yet, the target antigens of the pathogenic B-cell response in MS remain unclear. Recombinant:Article Title: Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis Article Snippet: Frozen supernatants from polyclonally stimulated B cells were delivered to Cambridge Protein Arrays Ltd. (Cambridge, United Kingdom). .. Samples were analyzed using HuProt v4.0 Article Title: Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis Article Snippet: Background and Objectives Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease of the CNS.. Highlighted by the success of B-cell–depleting therapies such as the monoclonal anti-CD20 antibodies rituximab, ocrelizumab, and ofatumumab, B cells have been shown to play a central role in the immunopathology of the disease.. Yet, the target antigens of the pathogenic B-cell response in MS remain unclear. other:Article Title: Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss Article Snippet: Article Title: Multiomics dissection of human RAG deficiency reveals distinctive patterns of immune dysregulation but a common inflammatory signature. Article Snippet: Marita Bosticardo†, Kerry Dobbs†, Ottavia M. Delmonte†, Andrew J. Martins‡, Francesca Pala, Tomoki Kawai§, Heather Kenney, Gloria Magro, Lindsey B. Rosen, Yasuhiro Yamazaki, HsinHui Yu, Enrica Calzoni, Yu Nee Lee, Can Liu‡, Jennifer Stoddard, Julie Niemela, Danielle Fink, Riccardo Castagnoli¶, Meredith Ramba, Aristine Cheng#, Deanna Riley, Vasileios Oikonomou, Elana Shaw, Brahim Belaid, Sevgi Keles, Waleed AlHerz, Caterina Cancrini, Cristina Cifaldi, Safa Baris, Svetlana Sharapova, Catharina Schuetz, Andrew R. Gennery, Alexandra F. Freeman, Raz Somech, Sharon Choo, Silvia C. Giliani, Tayfun Güngör, Daniel Drozdov, Isabelle Meyts, Despina Moshous, Benedicte Neven, Roshini S. Abraham, Aisha ElMarsafy, Maria Kanariou, Alejandra King, Francesco Licciardi, Mario E. CruzMuñoz, Paolo Palma, Cecilia Poli, Mehdi Adeli, Mattia Algeri**, Fayhan J. Alroqi, Paul Bastard, Jenna R. E. Bergerson, Claire Booth, Ana Brett, Siobhan O. Burns, Manish J. Butte, Nurcicek Padem, M. Teresa de la Morena, Ghassan Dbaibo, Suk See de Ravin, Dimana Dimitrova, Reda Djidjik, Mayra B. Dorna, Cullen M. Dutmer, Reem Elfeky, Fabio Facchetti, Ramsay L. Fuleihan, Raif S. Geha, Luis I. GonzalezGranado, Liis Haljasmägi, Hanadys Ale, Anthony Hayward, Anna M. Hifanova, Winnie Ip, Blanka Kaplan, Neena Kapoor, Elif KarakocAydiner, Jaanika Kärner, Michael D. Keller, Blachy J. Dávila Saldaña††, Ayça Kiykim, Taco W. Kuijpers, Elena E. Kuznetsova, Elena A. Latysheva, Jennifer W. Leiding, Franco Locatelli, Guisela AlvaLozada, Christine McCusker, Fatih Celmeli, Megan Morsheimer, Ahmet Ozen, Nima Parvaneh, Srdjan Pasic, Alessandro Plebani, Kahn Preece, Susan Prockop, Inga S. Sakovich, Elena E. Starkova, Troy Torgerson, James Verbsky, Jolan E. Walter, Brant Ward‡‡, Elizabeth L. Wisner, Deborah Draper, Katherine MyintHpu, Pooi M. Truong, Michail S. Lionakis, Morgan B. Similuk, Centralized Sequencing Program Group§§, Magdalena A. Walkiewicz, Amy Klion, Steven M. Holland, Cihan Oguz, Dusan Bogunovic, Kai Kisand, Helen C. Su, John S. Tsang‡, Douglas Kuhns, Anna Villa, Sergio D. Rosenzweig, Stefania Pittaluga, Luigi D. Notarangelo* Article Title: Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss. Article Snippet: Identification of dexamethasone binding proteins using |
